Is MOTS-c Legal in Tennessee?
HealthRX.com
Federal compounding limits still apply to MOTS-c in Tennessee
See the public record for MOTS-c
At a glance
- FDA approval / None; not a component of an approved drug [1]
- Studies in people / FDA found none in which MOTS-c was given to a person [1]
- FDA pharmacy bulk list / Not listed [2][6]
- FDA outsourcing-facility list / Not listed [3]
- Interim-policy categories / In none of the three [2][3][6]
- Advisory committee / July 23, 2026 vote favored listing; advice only [7][4]
- HHS draft / Covers injectable MOTS-c acetate; non-binding [4][5]
- Sport / WADA S4.4.1, prohibited at all times [8]
What MOTS-c is and where it stands federally
MOTS-c is a 16-amino-acid peptide, molecular weight about 2174.6 g/mol, encoded in mitochondrial DNA and first reported in 2015 by Lee et al. in Cell Metabolism [1][9]. It is not an FDA-approved drug and is not a component of one [1].
Federal restrictions on compounding MOTS-c apply in Tennessee. A state-licensed pharmacy may compound with a bulk substance only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's list of bulk substances that may be used in compounding [6]. MOTS-c meets none of those conditions [1][2]. It also appears in none of the categories on FDA's interim-policy list for outsourcing facilities [3].
Did the 2026 advisory vote or HHS draft change that?
The Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it, against FDA staff's recommendation; that advice is non-binding, MOTS-c is not on the list, and adding it takes formal rulemaking [7][4]. FDA staff had proposed not adding either form, citing no human safety or effectiveness data, no animal toxicity studies and no impurity or endotoxin data [1].
HHS's draft enforcement-discretion policy (filed October 28, 2026; Federal Register document 2026-22192; publication scheduled October 30, 2026) covers MOTS-c acetate given by subcutaneous or intramuscular injection. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with it if conditions are met, including a single active ingredient and a patient-specific prescription [4][5]. The notice says it establishes no rights and is not binding, and HHS may revisit it [4]. It is a draft, not an FDA approval, and it does not put MOTS-c on any list [4].
Questions worth asking
Have people been given MOTS-c?
FDA searched PubMed, Embase, the Cochrane library and other sources and found no published study in which MOTS-c was given to a person; the 12 papers the nominator cited were not clinical studies [1]. There are no pharmacokinetic data in humans or live animals, and one in-vitro study found MOTS-c is quickly broken down in human blood [1].
Human studies measured the body's own MOTS-c: one trial randomized 30 healthy adults to endurance exercise (n=10), resistance exercise (n=10) or control (n=10), and circulating MOTS-c showed only a trend to rise after endurance exercise [10]. In mice, MOTS-c prevented diet-induced obesity and insulin resistance [9]. There is no approved dose or human dosing study; the nominated products were 5 mg and 10 mg subcutaneous injections [1].
Safety and sport
FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports, but with no human exposure data and no animal toxicity studies its safety in people is unknown; the stated concern for injection is immunogenicity [1]. WADA names MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times in and out of competition, and it is on the 2026 and 2027 Lists [8][11].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is MOTS-c legal in Tennessee?
Can a Tennessee pharmacy compound MOTS-c?
Did the July 2026 advisory vote make it legal?
Has MOTS-c been given to people?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- Bulk Drug Substances Used in Compounding | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- World Anti-Doping Agency.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.